BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Del Prete M, Buteau FA, Arsenault F, Saighi N, Bouchard LO, Beaulieu A, Beauregard JM. Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: initial results from the P-PRRT trial. Eur J Nucl Med Mol Imaging 2019;46:728-42. [PMID: 30506283 DOI: 10.1007/s00259-018-4209-7] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 7.5] [Reference Citation Analysis]
Number Citing Articles
1 Roosen J, Westlund Gotby LEL, Arntz MJ, Fütterer JJ, Janssen MJR, Konijnenberg MW, van Wijk MWM, Overduin CG, Nijsen JFW. Intraprocedural MRI-based dosimetry during transarterial radioembolization of liver tumours with holmium-166 microspheres (EMERITUS-1): a phase I trial towards adaptive, image-controlled treatment delivery. Eur J Nucl Med Mol Imaging 2022. [PMID: 35829749 DOI: 10.1007/s00259-022-05902-w] [Reference Citation Analysis]
2 Haider M, Das S, Al-Toubah T, Pelle E, El-Haddad G, Strosberg J. Somatostatin receptor radionuclide therapy in neuroendocrine tumors. Endocr Relat Cancer 2021;28:R81-93. [PMID: 33608483 DOI: 10.1530/ERC-20-0360] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 de Vries-Huizing DMV, Versleijen MWJ, Sinaasappel M, Walraven I, Geluk-Jonker MM, Tesselaar MET, Hendrikx JJMA, de Wit-van der Veen BJ, Stokkel MPM. Haematotoxicity during peptide receptor radionuclide therapy: Baseline parameters differences and effect on patient's therapy course. PLoS One 2021;16:e0260073. [PMID: 34793530 DOI: 10.1371/journal.pone.0260073] [Reference Citation Analysis]
4 Nölting S, Ullrich M, Pietzsch J, Ziegler CG, Eisenhofer G, Grossman A, Pacak K. Current Management of Pheochromocytoma/Paraganglioma: A Guide for the Practicing Clinician in the Era of Precision Medicine. Cancers (Basel) 2019;11:E1505. [PMID: 31597347 DOI: 10.3390/cancers11101505] [Cited by in Crossref: 41] [Cited by in F6Publishing: 30] [Article Influence: 13.7] [Reference Citation Analysis]
5 Pandit-Taskar N, Iravani A, Lee D, Jacene H, Pryma D, Hope T, Saboury B, Capala J, Wahl RL. Dosimetry in Clinical Radiopharmaceutical Therapy of Cancer: Practicality Versus Perfection in Current Practice. J Nucl Med 2021;62:60S-72S. [PMID: 34857623 DOI: 10.2967/jnumed.121.262977] [Reference Citation Analysis]
6 Walrand S, Jamar F. Renal and Red Marrow Dosimetry in Peptide Receptor Radionuclide Therapy: 20 Years of History and Ahead. Int J Mol Sci 2021;22:8326. [PMID: 34361092 DOI: 10.3390/ijms22158326] [Reference Citation Analysis]
7 Derlin T, Bogdanova N, Ohlendorf F, Ramachandran D, Werner RA, Ross TL, Christiansen H, Bengel FM, Henkenberens C. Assessment of γ-H2AX and 53BP1 Foci in Peripheral Blood Lymphocytes to Predict Subclinical Hematotoxicity and Response in Somatostatin Receptor-Targeted Radionuclide Therapy for Advanced Gastroenteropancreatic Neuroendocrine Tumors. Cancers (Basel) 2021;13:1516. [PMID: 33806081 DOI: 10.3390/cancers13071516] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Te Beek ET, Burggraaf J, Teunissen JJM, Vriens D. Clinical Pharmacology of Radiotheranostics in Oncology. Clin Pharmacol Ther 2022. [PMID: 35373336 DOI: 10.1002/cpt.2598] [Reference Citation Analysis]
9 Desy A, Bouvet GF, Frezza A, Després P, Beauregard JM. Impact of dead time on quantitative 177Lu-SPECT (QSPECT) and kidney dosimetry during PRRT. EJNMMI Phys 2020;7:32. [PMID: 32415492 DOI: 10.1186/s40658-020-00303-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Staanum PF, Frellsen AF, Olesen ML, Iversen P, Arveschoug AK. Practical kidney dosimetry in peptide receptor radionuclide therapy using [177Lu]Lu-DOTATOC and [177Lu]Lu-DOTATATE with focus on uncertainty estimates. EJNMMI Phys 2021;8:78. [PMID: 34773508 DOI: 10.1186/s40658-021-00422-2] [Reference Citation Analysis]
11 Minczeles NS, de Herder WW, Konijnenberg MW, Feelders RA, Brabander T, Hofland J. Dose-Limiting Bone Marrow Toxicities After Peptide Receptor Radionuclide Therapy Are More Prevalent in Women Than in Men. Clin Nucl Med 2022;Publish Ahead of Print. [DOI: 10.1097/rlu.0000000000004203] [Reference Citation Analysis]
12 Götz TI, Lang EW, Schmidkonz C, Maier A, Kuwert T, Ritt P. Particle filter de-noising of voxel-specific time-activity-curves in personalized 177Lu therapy. Z Med Phys 2020;30:116-34. [PMID: 31859029 DOI: 10.1016/j.zemedi.2019.10.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
13 Wahl RL, Sgouros G, Iravani A, Jacene H, Pryma D, Saboury B, Capala J, Graves SA. Normal-Tissue Tolerance to Radiopharmaceutical Therapies, the Knowns and the Unknowns. J Nucl Med 2021;62:23S-35S. [PMID: 34857619 DOI: 10.2967/jnumed.121.262751] [Reference Citation Analysis]
14 Ritt P, Jobic C, Beck M, Schmidkonz C, Kuwert T, Uder M, Brand M. Dissimilar DNA Damage to Blood Lymphocytes After 177Lu-Labeled DOTATOC or Prostate-Specific Membrane Antigen Therapy. J Nucl Med 2021;62:379-85. [PMID: 32737244 DOI: 10.2967/jnumed.120.243782] [Reference Citation Analysis]
15 Lawhn-heath C, Hope TA, Martinez J, Fung EK, Shin J, Seo Y, Flavell RR. Dosimetry in radionuclide therapy: the clinical role of measuring radiation dose. The Lancet Oncology 2022;23:e75-87. [DOI: 10.1016/s1470-2045(21)00657-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
16 Bodei L, Bergsland E, de Herder WW, Ferone D, Hicks RJ, Hope TA, Kunikowska J, Pavel M, Reidy-Lagunes D, Siveke J, Strosberg J, Dittmer U, Herrmann K. Peptide Receptor Radionuclide Therapy During the COVID-19 Pandemic: Are There Any Concerns? J Nucl Med 2020;61:1094-5. [PMID: 32576637 DOI: 10.2967/jnumed.120.249136] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
17 Bushnell DL, Bodeker KL. Overview and Current Status of Peptide Receptor Radionuclide Therapy. Surg Oncol Clin N Am 2020;29:317-26. [PMID: 32151363 DOI: 10.1016/j.soc.2019.11.005] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
18 Kristiansson A, Örbom A, Vilhelmsson Timmermand O, Ahlstedt J, Strand SE, Åkerström B. Kidney Protection with the Radical Scavenger α1-Microglobulin (A1M) during Peptide Receptor Radionuclide and Radioligand Therapy. Antioxidants (Basel) 2021;10:1271. [PMID: 34439519 DOI: 10.3390/antiox10081271] [Reference Citation Analysis]
19 Beykan S, Tran-Gia J, Borup Jensen S, Lassmann M. Is a single late SPECT/CT based kidney 177Lu-dosimetry superior to hybrid dosimetry with sequential multiple time-point whole-body planar scans in combination with an early SPECT/CT? Phys Med 2022;100:39-50. [PMID: 35724608 DOI: 10.1016/j.ejmp.2022.06.002] [Reference Citation Analysis]
20 Terry SYA, Nonnekens J, Aerts A, Baatout S, de Jong M, Cornelissen B, Pouget J. Call to arms: need for radiobiology in molecular radionuclide therapy. Eur J Nucl Med Mol Imaging 2019;46:1588-90. [DOI: 10.1007/s00259-019-04334-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
21 Sjögreen Gleisner K, Chouin N, Gabina PM, Cicone F, Gnesin S, Stokke C, Konijnenberg M, Cremonesi M, Verburg FA, Bernhardt P, Eberlein U, Gear J. EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands. Eur J Nucl Med Mol Imaging. [DOI: 10.1007/s00259-022-05727-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
22 Malcolm JC, Falzone N, Gains JE, Aldridge MD, Mirando D, Lee BQ, Gaze MN, Vallis KA. Impact of cyclic changes in pharmacokinetics and absorbed dose in pediatric neuroblastoma patients receiving [177Lu]Lu-DOTATATE. EJNMMI Phys 2022;9. [DOI: 10.1186/s40658-022-00436-4] [Reference Citation Analysis]
23 Del Olmo-Garcia MI, Prado-Wohlwend S, Andres A, Soriano JM, Bello P, Merino-Torres JF. Somatostatin and Somatostatin Receptors: From Signaling to Clinical Applications in Neuroendocrine Neoplasms. Biomedicines 2021;9:1810. [PMID: 34944626 DOI: 10.3390/biomedicines9121810] [Reference Citation Analysis]
24 Haider M, Al-Toubah T, El-Haddad G, Strosberg J. Molecular imaging and radionuclide therapy of neuroendocrine tumors. Curr Opin Endocrinol Diabetes Obes 2020;27:16-21. [PMID: 31789833 DOI: 10.1097/MED.0000000000000519] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
25 Frezza A, Desport C, Uribe C, Zhao W, Celler A, Després P, Beauregard JM. Comprehensive SPECT/CT system characterization and calibration for 177Lu quantitative SPECT (QSPECT) with dead-time correction. EJNMMI Phys 2020;7:10. [PMID: 32060777 DOI: 10.1186/s40658-020-0275-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
26 Adant S, Shah GM, Beauregard J. Combination treatments to enhance peptide receptor radionuclide therapy of neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2020;47:907-21. [DOI: 10.1007/s00259-019-04499-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
27 Ahmadi Bidakhvidi N, Goffin K, Dekervel J, Baete K, Nackaerts K, Clement P, Van Cutsem E, Verslype C, Deroose CM. Peptide Receptor Radionuclide Therapy Targeting the Somatostatin Receptor: Basic Principles, Clinical Applications and Optimization Strategies. Cancers (Basel) 2021;14:129. [PMID: 35008293 DOI: 10.3390/cancers14010129] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Peters SMB, Privé BM, de Bakker M, de Lange F, Jentzen W, Eek A, Muselaers CHJ, Mehra N, Witjes JA, Gotthardt M, Nagarajah J, Konijnenberg MW. Intra-therapeutic dosimetry of [177Lu]Lu-PSMA-617 in low-volume hormone-sensitive metastatic prostate cancer patients and correlation with treatment outcome. Eur J Nucl Med Mol Imaging 2021. [PMID: 34218300 DOI: 10.1007/s00259-021-05471-4] [Reference Citation Analysis]
29 Minczeles NS, Hofland J, de Herder WW, Brabander T. Strategies Towards Improving Clinical Outcomes of Peptide Receptor Radionuclide Therapy. Curr Oncol Rep 2021;23:46. [PMID: 33721105 DOI: 10.1007/s11912-021-01037-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Sundlöv A, Gleisner KS, Tennvall J, Ljungberg M, Warfvinge CF, Holgersson K, Hallqvist A, Bernhardt P, Svensson J. Phase II trial demonstrates the efficacy and safety of individualized, dosimetry-based 177Lu-DOTATATE treatment of NET patients. Eur J Nucl Med Mol Imaging 2022. [PMID: 35451612 DOI: 10.1007/s00259-022-05786-w] [Reference Citation Analysis]
31 Sandström M, Freedman N, Fröss-Baron K, Kahn T, Sundin A. Kidney dosimetry in 777 patients during 177Lu-DOTATATE therapy: aspects on extrapolations and measurement time points. EJNMMI Phys 2020;7:73. [PMID: 33296054 DOI: 10.1186/s40658-020-00339-2] [Reference Citation Analysis]
32 Cicone F, Gnesin S, Cremonesi M. Dosimetry of nuclear medicine therapies: current controversies and impact on treatment optimization. Q J Nucl Med Mol Imaging 2021;65:327-32. [PMID: 34881850 DOI: 10.23736/S1824-4785.21.03418-X] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
33 Sistani G, Sutherland DEK, Mujoomdar A, Wiseman DP, Khatami A, Tsvetkova E, Reid RH, Laidley DT. Efficacy of 177Lu-Dotatate Induction and Maintenance Therapy of Various Types of Neuroendocrine Tumors: A Phase II Registry Study. Curr Oncol 2020;28:115-27. [PMID: 33622997 DOI: 10.3390/curroncol28010015] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
34 Telo S, Filice A, Versari A, Lamberti G, Campana D, Calabrò D, Fanti S, Ambrosini V. Peptide receptor radionuclide therapy for GEP-NET: consolidated knowledge and innovative applications. Clin Transl Imaging 2021;9:423-38. [DOI: 10.1007/s40336-021-00443-y] [Reference Citation Analysis]
35 Hope TA, Pavel M, Bergsland EK. Neuroendocrine Tumors and Peptide Receptor Radionuclide Therapy: When Is the Right Time? J Clin Oncol 2022;:JCO2200176. [PMID: 35649195 DOI: 10.1200/JCO.22.00176] [Reference Citation Analysis]
36 Nilica B, Svirydenka A, Fritz J, Bayerschmidt S, Kroiss A, Gruber L, Virgolini IJ. Nephrotoxicity and hematotoxicity one year after four cycles of peptide receptor radionuclide therapy (PRRT) and its impact on future treatment planning — A retrospective analysis. Revista Española de Medicina Nuclear e Imagen Molecular (English Edition) 2021. [DOI: 10.1016/j.remnie.2021.04.007] [Reference Citation Analysis]
37 O'Neill E, Kersemans V, Allen PD, Terry SYA, Torres JB, Mosley M, Smart S, Lee BQ, Falzone N, Vallis KA, Konijnenberg MW, de Jong M, Nonnekens J, Cornelissen B. Imaging DNA Damage Repair In Vivo After 177Lu-DOTATATE Therapy. J Nucl Med 2020;61:743-50. [PMID: 31757844 DOI: 10.2967/jnumed.119.232934] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
38 Kennedy J, Chicheportiche A, Keidar Z. Quantitative SPECT/CT for dosimetry of peptide receptor radionuclide therapy. Semin Nucl Med 2021:S0001-2998(21)00091-X. [PMID: 34911637 DOI: 10.1053/j.semnuclmed.2021.11.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
39 Zhang J, Song Q, Cai L, Xie Y, Chen Y. The efficacy of 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) in patients with metastatic neuroendocrine tumours: a systematic review and meta-analysis. J Cancer Res Clin Oncol 2020;146:1533-43. [PMID: 32281025 DOI: 10.1007/s00432-020-03181-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
40 Nilica B, Svirydenka A, Fritz J, Bayerschmidt S, Kroiss AS, Gruber L, Virgolini IJ. Nephrotoxicity and hematotoxicity one year after four cycles of peptide receptor radionuclide therapy (PRRT) and its impact on future treatment planning. A retrospective analysis. Rev Esp Med Nucl Imagen Mol 2021:S2253-654X(21)00062-7. [PMID: 34384731 DOI: 10.1016/j.remn.2021.03.004] [Reference Citation Analysis]
41 Graves SA, Hobbs RF. Dosimetry for Optimized, Personalized Radiopharmaceutical Therapy. Semin Radiat Oncol 2021;31:37-44. [PMID: 33246635 DOI: 10.1016/j.semradonc.2020.07.008] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
42 Opalińska M, Sowa-Staszczak A, Grochowska A, Olearska H, Hubalewska-Dydejczyk A. Value of Peptide Receptor Radionuclide Therapy as Neoadjuvant Treatment in the Management of Primary Inoperable Neuroendocrine Tumors. Front Oncol 2021;11:687925. [PMID: 34868906 DOI: 10.3389/fonc.2021.687925] [Reference Citation Analysis]
43 Marinova M, Mücke M, Fischer F, Essler M, Cuhls H, Radbruch L, Ghaei S, Conrad R, Ahmadzadehfar H. Quality of life in patients with midgut NET following peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging 2019;46:2252-9. [PMID: 31338547 DOI: 10.1007/s00259-019-04431-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
44 Desy A, Bouvet GF, Croteau É, Lafrenière N, Turcotte ÉE, Després P, Beauregard JM. Quantitative SPECT (QSPECT) at high count rates with contemporary SPECT/CT systems. EJNMMI Phys 2021;8:73. [PMID: 34718900 DOI: 10.1186/s40658-021-00421-3] [Reference Citation Analysis]
45 Bushnell DL, Bodeker KL, O'Dorisio TM, Madsen MT, Menda Y, Graves S, Zamba GKD, O'Dorisio MS. Addition of 131I-MIBG to PRRT (90Y-DOTATOC) for Personalized Treatment of Selected Patients with Neuroendocrine Tumors. J Nucl Med 2021;62:1274-7. [PMID: 33517327 DOI: 10.2967/jnumed.120.254987] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
46 Ritt P, Kuwert T. Quantitative SPECT/CT-Technique and Clinical Applications. Recent Results Cancer Res 2020;216:565-90. [PMID: 32594399 DOI: 10.1007/978-3-030-42618-7_17] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
47 Sundlöv A, Sjögreen-Gleisner K. Peptide Receptor Radionuclide Therapy - Prospects for Personalised Treatment. Clin Oncol (R Coll Radiol) 2021;33:92-7. [PMID: 33189510 DOI: 10.1016/j.clon.2020.10.020] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
48 Geenen L, Nonnekens J, Konijnenberg M, Baatout S, De Jong M, Aerts A. Overcoming nephrotoxicity in peptide receptor radionuclide therapy using [177Lu]Lu-DOTA-TATE for the treatment of neuroendocrine tumours. Nucl Med Biol 2021;102-103:1-11. [PMID: 34242948 DOI: 10.1016/j.nucmedbio.2021.06.006] [Reference Citation Analysis]
49 Fortunati E, Argalia G, Zanoni L, Fanti S, Ambrosini V. New PET Radiotracers for the Imaging of Neuroendocrine Neoplasms. Curr Treat Options Oncol 2022. [PMID: 35325412 DOI: 10.1007/s11864-022-00967-z] [Reference Citation Analysis]
50 Hou X, Zhao W, Beauregard JM, Celler A. Personalized kidney dosimetry in 177Lu-octreotate treatment of neuroendocrine tumours: a comparison of kidney dosimetry estimates based on a whole organ and small volume segmentations. Phys Med Biol 2019;64:175004. [PMID: 31456584 DOI: 10.1088/1361-6560/ab32a1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
51 Giraudet AL, Kryza D, Hofman M, Moreau A, Fizazi K, Flechon A, Hicks RJ, Tran B. PSMA targeting in metastatic castration-resistant prostate cancer: where are we and where are we going? Ther Adv Med Oncol 2021;13:17588359211053898. [PMID: 34721674 DOI: 10.1177/17588359211053898] [Reference Citation Analysis]